Teradyne director sells 1,200 shares in preset trade

Teradyne director Marilyn Matz executed an open-market sale of 1,200 shares of common stock at $356.31 per share on July 15, 2026.

Rhea-AI Filing Summary

Teradyne director Marilyn Matz executed an open-market sale of 1,200 shares of common stock at $356.31 per share on July 15, 2026. Following the sale, she holds 16,240.675 shares directly. The transaction was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 13, 2026.

Insider Trade Summary 10b5-1

Net Seller: 1,200 shares

Net Sell 1 txn

Insider MATZ MARILYN

Role Director

Sold 1,200 shs ($428K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	1,200	$356.31	$428K

Holdings After Transaction: Common Stock — 16,240.675 shares (Direct)

Footnotes (1)

1. F1. The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person on February 13, 2026 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

Key Figures

Shares sold: 1,200 shares Sale price: $356.31 per share Shares held after sale: 16,240.675 shares +3 more

6 metrics

Shares sold 1,200 shares Open-market sale of Teradyne common stock by director Marilyn Matz on July 15, 2026

Sale price $356.31 per share Average price for the 1,200 Teradyne shares sold in the reported transaction

Shares held after sale 16,240.675 shares Director Marilyn Matz’s direct Teradyne holdings following the reported sale

Net shares sold 1,200 shares Net buy/sell activity in the transaction summary for this reporting period

Transactions classified as sales 1 One non-derivative open-market sale reported; no buys, exercises, or gifts

10b5-1 plan adoption date February 13, 2026 Date the sales plan intended to comply with Rule 10b5-1 was adopted

Key Terms

open-market sale, Rule 10b5-1, Securities Exchange Act of 1934, sales plan

4 terms

open-market sale financial

"classified as an open-market sale of common stock"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Rule 10b5-1 regulatory

"intended to comply with Rule 10b5-1 under the Securities"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

Securities Exchange Act of 1934 regulatory

"under the Securities Exchange Act of 1934"

sales plan financial

"The reported transaction was effected pursuant to a sales plan adopted"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Teradyne (TER) director Marilyn Matz report?

Director Marilyn Matz reported an open-market sale of Teradyne common stock. She sold 1,200 shares on July 15, 2026, and the trade was executed under a Rule 10b5-1 pre-arranged sales plan adopted earlier that year.

How many Teradyne (TER) shares did Marilyn Matz sell and at what price?

Marilyn Matz sold 1,200 Teradyne shares at an average price of $356.31 per share. The transaction is classified as an open-market sale of common stock and is disclosed as a non-derivative transaction.

How many Teradyne (TER) shares does Marilyn Matz hold after the reported sale?

After the reported transaction, Marilyn Matz directly holds 16,240.675 Teradyne common shares. This figure represents her post-transaction direct ownership as disclosed, following the sale of 1,200 shares in the open market.

Was the Teradyne (TER) insider sale by Marilyn Matz under a Rule 10b5-1 trading plan?

Yes. The filing states the sale was made under a sales plan adopted on February 13, 2026 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, indicating a pre-arranged trading arrangement.

Did the Teradyne (TER) filing show any option exercises or derivative transactions for Marilyn Matz?

No derivative transactions are listed for this report. The filing discloses a single non-derivative open-market sale of 1,200 shares of Teradyne common stock, and the derivative transaction count in the summary is reported as zero.

How many shares in total did Marilyn Matz trade in Teradyne (TER) in this filing?

This Form 4 reports 1,200 shares sold and no purchases, exercises, or gifts. The transaction summary shows a net-sell of 1,200 shares, reflecting one open-market sale and no other types of transactions during the reported period.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/16/2026 - 01:17 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MATZ MARILYN

(Last) (First) (Middle)

C/O TERADYNE, INC.

600 RIVERPARK DRIVE

(Street)

NORTH READING MASSACHUSETTS 01864

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TERADYNE, INC [ TER ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/15/2026		S(1)		1,200	D	$356.31	16,240.675	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person on February 13, 2026 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

	/s/ Ryan E. Driscoll, Attorney-in-Fact	07/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)